Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Non Operating Income (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Non Operating Income for 6 consecutive years, with $10.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 18.73% to $10.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.0 million, a 47.53% increase, with the full-year FY2025 number at $44.0 million, up 47.53% from a year prior.
  • Non Operating Income was $10.5 million for Q4 2025 at Janux Therapeutics, down from $10.9 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $11.4 million in Q1 2025 to a low of $46000.0 in Q2 2021.
  • A 5-year average of $4.9 million and a median of $4.2 million in 2023 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: surged 2874.32% in 2022, then rose 18.73% in 2025.
  • Janux Therapeutics' Non Operating Income stood at $74000.0 in 2021, then soared by 2874.32% to $2.2 million in 2022, then soared by 98.96% to $4.4 million in 2023, then soared by 101.1% to $8.8 million in 2024, then grew by 18.73% to $10.5 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Non Operating Income are $10.5 million (Q4 2025), $10.9 million (Q3 2025), and $11.3 million (Q2 2025).